Literature DB >> 10433493

Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition.

V Pérez1, J L Marco, E Fernández-Alvarez, M Unzeta.   

Abstract

1. Previous studies with indolyl derivatives as monoamine oxidase (MAO) inhibitors have shown the relevance of the indole structure for recognition by the active site of this enzyme. We now report a new series of molecules with structural features which determine the selectivity of MAO inhibition. 2. A benzyloxy group attached at position 5 of the indole ring is critical for this selective behaviour. Amongst all of these benzyloxy-indolyl methylamines, N-(2-propynyl)-2-(5-benzyloxyindol)methylamine FA-73 was the most potent MAO-B 'suicide' inhibitor studied. 3. The Ki values for MAO-A and MAO-B were 800+/-60 and 0.75+/-0.15 nM, respectively. These data represent a selectivity value of 1066 for MAO-B, being 48 times more selective than L-deprenyl (Ki values of 376+/-0.032 and 16.8+/-0.1 nM for MAO A and MAO-B, respectively). The IC50 values for dopamine uptake in striatal synaptosomal fractions from rats were 150+/-8 microM for FA-73 and 68 +/- 10 microM for L-deprenyl whereas in human caudate tissue the IC50 values were 0.36+/-0.015 microM for FA-73 and 0.10+/-0.007 microM for L-deprenyl. Moreover, mouse brain MAO-B activity was 90% ex vivo inhibited by both compounds 1 h after 4 mg kg(-1) administration, MAO-A activity was not affected. 4. These novel molecules should provide a better understanding of the active site of monoamine oxidase and could be the starting point for the design of further selective, non-amphetamine-like MAO-B inhibitors with therapeutic potential for the treatment of neurological disorders.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10433493      PMCID: PMC1566084          DOI: 10.1038/sj.bjp.0702600

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  31 in total

1.  Probing the active sites of monoamine oxidase A and B with 1,4-disubstituted tetrahydropyridine substrates and inactivators.

Authors:  S L Palmer; S Mabic; N Castagnoli
Journal:  J Med Chem       Date:  1997-06-20       Impact factor: 7.446

2.  cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties.

Authors:  A W Bach; N C Lan; D L Johnson; C W Abell; M E Bembenek; S W Kwan; P H Seeburg; J C Shih
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

3.  Some observations upon a new inhibitor of monoamine oxidase in brain tissue.

Authors:  J P Johnston
Journal:  Biochem Pharmacol       Date:  1968-07       Impact factor: 5.858

4.  Concentration dependence of the oxidation of tyramine by the two forms of rat liver mitochondrial monoamine oxidase.

Authors:  C J Fowler; K F Tipton
Journal:  Biochem Pharmacol       Date:  1981-12-15       Impact factor: 5.858

5.  A rapid method for preparing synaptosomes: comparison, with alternative procedures.

Authors:  P R Dodd; J A Hardy; A E Oakley; J A Edwardson; E K Perry; J P Delaunoy
Journal:  Brain Res       Date:  1981-12-07       Impact factor: 3.252

6.  Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: specific inhibitors of dopamine uptake.

Authors:  R E Heikkila; L Manzino
Journal:  Eur J Pharmacol       Date:  1984-08-17       Impact factor: 4.432

7.  Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.

Authors:  J A Javitch; R J D'Amato; S M Strittmatter; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

8.  A comparative study of some kinetic and molecular properties of microsomal and mitochondrial monoamine oxidase.

Authors:  N Gómez; D Balsa; M Unzeta
Journal:  Biochem Pharmacol       Date:  1988-09-15       Impact factor: 5.858

9.  The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline.

Authors:  C J Fowler; T J Mantle; K F Tipton
Journal:  Biochem Pharmacol       Date:  1982-11-15       Impact factor: 5.858

10.  Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors.

Authors:  R E Heikkila; L Manzino; F S Cabbat; R C Duvoisin
Journal:  Nature       Date:  1984 Oct 4-10       Impact factor: 49.962

View more
  13 in total

1.  The proof-of-concept of ASS234: Peripherally administered ASS234 enters the central nervous system and reduces pathology in a male mouse model of Alzheimer disease.

Authors:  Mari Paz Serrano; Raquel Herrero-Labrador; Hunter S Futch; Julia Serrano; Alejandro Romero; Ana Patricia Fernandez; Abdelouahid Samadi; Mercedes Unzeta; Jose Marco-Contelles; Ricardo Martínez-Murillo
Journal:  J Psychiatry Neurosci       Date:  2017-01       Impact factor: 6.186

2.  Predicting targets of compounds against neurological diseases using cheminformatic methodology.

Authors:  Katarina Nikolic; Lazaros Mavridis; Oscar M Bautista-Aguilera; José Marco-Contelles; Holger Stark; Maria do Carmo Carreiras; Ilaria Rossi; Paola Massarelli; Danica Agbaba; Rona R Ramsay; John B O Mitchell
Journal:  J Comput Aided Mol Des       Date:  2014-11-26       Impact factor: 3.686

3.  An MCASE approach to the search of a cure for Parkinson's Disease.

Authors:  Gilles Klopman; Aleksandr Sedykh
Journal:  BMC Pharmacol       Date:  2002-04-02

4.  Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches.

Authors:  Pablo Duarte; Antonio Cuadrado; Rafael León
Journal:  Handb Exp Pharmacol       Date:  2021

5.  Design, synthesis, and evaluation of 3,7-substituted coumarin derivatives as multifunctional Alzheimer's disease agents.

Authors:  Sheunopa C Mzezewa; Sylvester I Omoruyi; Luke S Zondagh; Sarel F Malan; Okobi E Ekpo; Jacques Joubert
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

Review 6.  Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease.

Authors:  Natalia Guzior; Anna Wieckowska; Dawid Panek; Barbara Malawska
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

7.  Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids.

Authors:  Oscar M Bautista-Aguilera; Gerard Esteban; Mourad Chioua; Katarina Nikolic; Danica Agbaba; Ignacio Moraleda; Isabel Iriepa; Elena Soriano; Abdelouahid Samadi; Mercedes Unzeta; José Marco-Contelles
Journal:  Drug Des Devel Ther       Date:  2014-10-13       Impact factor: 4.162

Review 8.  Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease.

Authors:  Mercedes Unzeta; Gerard Esteban; Irene Bolea; Wieslawa A Fogel; Rona R Ramsay; Moussa B H Youdim; Keith F Tipton; José Marco-Contelles
Journal:  Front Neurosci       Date:  2016-05-25       Impact factor: 4.677

Review 9.  One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug.

Authors:  Rebecca E Hughes; Katarina Nikolic; Rona R Ramsay
Journal:  Front Neurosci       Date:  2016-04-25       Impact factor: 4.677

10.  ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy.

Authors:  José Marco-Contelles; Mercedes Unzeta; Irene Bolea; Gerard Esteban; Rona R Ramsay; Alejandro Romero; Ricard Martínez-Murillo; M Carmo Carreiras; Lhassane Ismaili
Journal:  Front Neurosci       Date:  2016-06-28       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.